Novo Nordisk (NVO) Revenue Impact from Semaglutide at 75% in 2026
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowMorgan Stanley downgraded Novo Nordisk A/S (NVO) to Underweight on September 11, 2026, citing that Semaglutide contributes roughly 75% of the company's revenue for 2026. The firm anticipates that this will drop to 59% by 2031 when the patent expires. Novo's stock is currently trading at a P/E ratio of 10.6 and has fallen 33% from its 52-week high, slipping an additional 2% after the downgrade. This information matters for investors because the shift in revenue sources post-patent expiration could significantly affect Novo's future earnings and valuation.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Understand this kind of story
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
